SCLC drug market wil more than double to $648M in 2017
The small-cell lung cancer drug market will more than double from just under $250.0 million in 2007 to more than $684.0 million in 2017, owing to the launches of Genentech/Roche/Chugai's Avastin (bevacizumab) and Celgene's amrubicin (currently marketed in Japan as Calsed by Nippon Kayaku) to treat the indication, according to a new report from research and market advisory firm Decision Resources.
The new Pharmacor report, entitled Small-Cell Lung Cancer, finds that the launches, beginning in 2012, of Avastin as a first-line add-on to standard chemotherapy and amrubicin as a second-line therapy will drive robust 22% annual growth from 2012 to 2017 in the USA, France, Germany, Italy, Spain, the UK and Japan.
SCLC drug developments disappointing
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze